Medindia
Medindia LOGIN REGISTER
Advertisement

Angelini Labopharm Announces the U.S. Launch of OLEPTRO™ for the Treatment of Major Depressive Disorder in Adults

Tuesday, August 10, 2010 Mental Health News
Advertisement
OLEPTRO™ Now Available as a New Treatment Option for MDD

For Media Inquiries (Angelini Labopharm)

For Labopharm Investor Relations Inquiries

Michael Parks

Lawrence Chamberlain

Vox Medica, Inc.

Investor Relations

Tel: (267) 885-3066

Tel:  (416) 815-0700

[email protected]

[email protected]

For Media Inquiries (Angelini)

Fabio Pieroni

Angelini Corporate Communications Director

Tel: +39 06 78053366

[email protected]

Sponsored Post and Backlink Submission


Latest Press Release on Mental Health News

This site uses cookies to deliver our services.By using our site, you acknowledge that you have read and understand our Cookie Policy, Privacy Policy, and our Terms of Use  Ok, Got it. Close